NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on neurological disorders, announced a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating next-generation epilepsy therapies using the company's sEEG-based platform. The program, led by Dr. Sandipan Pati, Professor and Epilepsy Division Director, will test novel therapeutics delivered locally into specific brain regions involved in sustaining seizures. The goal is to improve clinical efficacy while lowering systemic toxicity and off-target effects.
“Localized intracerebral delivery of therapeutics represents an important emerging direction for improving precision in epilepsy treatment while minimizing systemic side effects,” said Dr. Pati. “In our clinical practice, we use FDA-cleared intracranial electrodes for recording brain activity and performing therapeutic interventions such as stimulation and ablation. In parallel, our current research is focused on preclinical studies evaluating the feasibility, safety, and physiological effects of intracerebral drug infusion using minimally invasive intracranial platforms, including ultra-thin electrode-based systems designed to reduce tissue disruption.”
The collaboration is expected to begin in large animal models and, if primary objectives are met, progress to human studies. Dr. Pati noted that these preclinical studies aim to understand how targeted delivery influences seizure networks and brain–body interactions. If successful, the approach may inform future translational efforts towards a human study to develop more precise and individualized therapies for patients with epilepsy.
“The University of Minnesota is at the forefront of next-generation epilepsy research,” said Dave Rosa, President and CEO of NeuroOne. “As we continue advancing our preclinical drug delivery platform toward commercial readiness, we believe this collaboration will support development of a first-in-human study utilizing our technology for intracerebral treatment of epileptic seizures. If successful, this approach could redefine seizure care and establish a new era of precision brain-directed therapy.”
NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions offer combination diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery and spinal cord stimulation programs. More information is available at nmtc1.com.
This collaboration highlights a significant step towards precision brain-directed therapy. By targeting drug delivery directly to seizure foci, the approach could reduce systemic side effects common with oral anti-epileptic drugs. The potential translation to human studies could offer new hope for patients with drug-resistant epilepsy, a condition affecting millions worldwide.
